Key result
Canagliflozin demonstrates consistent heart failure benefits across preserved and reduced ejection fraction in type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Investigates canagliflozin outcomes across preserved and reduced ejection fraction heart failure in type 2 diabetes, highlighting uncertain spectrum-wide benefits.
Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF).1 Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabetes deemed to be at high risk based on established cardiovascular disease or multiple risk factors.2-4 However, it is unclear whether benefits are experienced across the broad spectrum of HF patients that includes those with preserved (HFpEF) as well as reduced ejection fraction (HFrEF).
No takes yet. Share an insight, caveat, or question.
Figtree et al. (2019) studied Type 2 diabetes mellitus and heart failure (HFpEF and HFrEF). Canagliflozin was evaluated on Heart failure outcomes associated with preserved and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: